LGND
$113.25
Ligand Pharm
$.05
.04%
LGND
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  $0.56
Revenue:  N/A
Monday
Nov 2
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Monday, August 3, 2020

What do you expect when LGND reports earnings?
Beat
Meet
Miss

Where is LGND's stock price going from here?
Up
Flat
Down
Stock chart of LGND
Analysts
Summary of analysts' recommendations for LGND
Score
Grade
Pivots
Resistance
$118.96
$117.29
$115.25

$113.58

Support
$111.54
$109.87
$107.83
Tweet
Growth
Description
Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalJohnson & JohnsonZoetisBristol-Myers SquibbUltragenyx PharmaceuticalCatalentMerck & Co.